Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022

2024/01/02 by Yi‐Chu Chen, Yi-Chu Chen, Peter Malfertheiner +26 · 30 citations
Medicine · #Helicobacter pylori-related gastroenterology studies #Gastric Cancer Management and Outcomes #Esophageal Cancer Research and Treatment

paper · pdf · doi:10.1053/j.gastro.2023.12.022

Citations

• Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report

Cited by

• Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers
• Helicobacter pylori in oral and gastric pathologies: a narrative review of potential bidirectional pathogenic interactions
• Androgen Signaling in Type 2 Innate Lymphoid Cells Drives Sex Differences in Helicobacter -Induced Gastric Inflammation and Atrophy
• Metabolic signatures for gastric cancer diagnosis and mechanistic insights: a multicenter study
• Racial and Ethnic Differences in Gastric Cancer by Stage of Diagnosis in the United States (2009–2019)
• Helicobacter pylori : A Contemporary Perspective on Pathogenesis, Diagnosis and Treatment Strategies. [europepmc]
• Current Knowledge about Gastric Microbiota with Special Emphasis on Helicobacter pylori- Related Gastric Conditions. [europepmc]
• Novel therapeutic regimens against Helicobacter pylori : an updated systematic review. [europepmc]
• Population-Based Study of Gastric Cancer Survival and Associations in Rural Western Honduras. [europepmc]
• Antitumor Effects of Resveratrol Opposing Mechanisms of Helicobacter pylori in Gastric Cancer. [europepmc]
• The Impact of Tobacco Smoking and Alcohol Consumption on the Development of Gastric Cancers. [europepmc]
• AUF1-mediated inhibition of autophagic lysosomal degradation contributes to CagA stability and Helicobacter pylori -induced inflammation. [europepmc]
• Role of ursolic acid in preventing gastrointestinal cancer: recent trends and future perspectives. [europepmc]
• Cardiovascular and Neurological Diseases and Association with Helicobacter Pylori Infection-An Overview. [europepmc]
• Where are we with gastric cancer screening in Europe in 2024? [europepmc]
• Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis. [europepmc]
• Gut microbiota and Parkinson's disease. [europepmc]
• Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population-Based Nationwide Cohort Study in Sweden. [europepmc]
• Infection of Helicobacter pylori contributes to the progression of gastric cancer through ferroptosis. [europepmc]
• Shattering the monolith: burden of gastrointestinal cancer in Asian Americans, Native Hawaiians, and Pacific Islanders in the United States. [europepmc]
• Helicobacter pylori -targeted AI-driven vaccines: a paradigm shift in gastric cancer prevention. [europepmc]
• Common diagnostic biomarkers and molecular mechanisms of Helicobacter pylori infection and inflammatory bowel disease. [europepmc]
• The role of MAPK pathway in gastric cancer: unveiling molecular crosstalk and therapeutic prospects. [europepmc]
• Helicobacter pylori eradication for primary prevention of gastric cancer: progresses and challenges. [europepmc]
• Ten-day vonoprazan-amoxicillin dual therapy versus 14-day esomeprazole-amoxicillin dual therapy for first-line Helicobacter pylori eradication: a prospective multicenter randomized controlled trial. [europepmc]
• Helicobacter pylori infection promotes M1 macrophage polarization and gastric inflammation by activation of NLRP3 inflammasome via TNF/TNFR1 axis. [europepmc]
• Environmental factors inducing gastric cancer: insights into risk and prevention strategies. [europepmc]
• Helicobacter pylori and gastric cancer: mechanisms and new perspectives. [europepmc]
• Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective. [europepmc]
• Korean Registry on the Current Management of Helicobacter pylori (K-Hp-Reg): Interim Analysis of Adherence to the Revised Evidence-Based Guidelines for First-Line Treatment. [europepmc]